ABIONYX Pharma Announces Its Financial Calendar for the Year 2026

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News:

ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces its financial calendar for 2026.

Events	Dates*
Cash position and activity update for Q4 2025	Thursday, February 26, 2026
2025 Full-Year Results	Thursday, March 12, 2026
Cash position and activity update for Q1 2026	Thursday, May 28, 2026
Cash position and activity update for Q2 2026	Thursday, August 27, 2026
2026 Half-Year Results	Thursday, September 24, 2026
Cash position and activity update for Q3 2026	Thursday, November 26, 2026
* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I–based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.